QIAGEN to Host Global TB Summit 2023: Advancing Tuberculosis Awareness and Action

QIAGEN to Host Global TB Summit 2023: Advancing Tuberculosis Awareness and Action

(IN BRIEF) QIAGEN is organizing the Global TB Clinical and Educational Summit 2023, running from October 17-19, with the theme “Tackling TB together: From awareness to action.” This summit highlights QIAGEN’s dedication to combat tuberculosis (TB) and address the gap between knowledge and practical measures in TB management, aligning with the United Nations High-Level Meeting’s ambitious goals against TB. The summit, accredited for Continuous Professional Development (CPD) and Continuing Medical Education (CME), aims to drive progress in TB management by providing healthcare professionals and policymakers with the latest insights and best practices. Key topics include ending TB by 2030, addressing TB in high-risk communities, post-COVID-19 TB challenges, and innovative diagnostic tools. Attendees will gain access to expert presentations, networking opportunities, emerging TB management tools and strategies, insights into pandemic challenges, and information on QIAGEN’s QuantiFERON-TB Gold Plus test, a vital tool in TB control. The event is free and offered both virtually and onsite in London.

(PRESS RELEASE) VENLO, 13-Oct-2023 — /EuropaWire/ — QIAGEN is set to host the Global TB Clinical and Educational Summit 2023 from October 17-19. This year’s theme, “Tackling TB together: From awareness to action”, underscores QIAGEN’s commitment to combating tuberculosis (TB) and emphasizes the need for bridging the gap between knowledge and tangible measures for TB management to achieve the ambitious goals recently outlined by the United Nations High-Level Meeting on the Fight Against Tuberculosis.

The CPD- and CME-accredited summit aims to drive significant advancements in the fight against TB and empower healthcare professionals and policymakers by providing them with the latest knowledge, insights, and best practices in TB management. Key topics include ending TB by 2030, addressing TB among high-risk communities, retaking the fight against TB after the COVID-19 pandemic, and exploring innovative diagnostic tools and strategies for expanding access to testing and treatment.

“Despite being curable and preventable, tuberculosis remains the second most lethal infectious disease after Covid-19. The Global TB Summit 2023 emphasizes the vital role of research and implementation of innovative technologies in combating tuberculosis. Now more than ever, we need to accelerate our collaborative efforts, harnessing the power of innovation and knowledge-sharing to defeat this deadly disease. We can only achieve a TB-free world by standing united and working hand-in-hand,” said Marc Destito, Vice President and Head of Global Health at QIAGEN.

By attending the Global TB Summit 2023, participants can expect:

• Access to expert presentations with globally renowned TB experts, covering research, clinical case studies, and advancements from various settings including high TB burden areas

• Opportunities for networking and collaboration with peers, healthcare professionals, policymakers, and TB survivors worldwide.

• Exposure to emerging tools and strategies for TB management, novel diagnostic approaches, cost-effective testing implementation, and expanded access to treatment options.

• Insights into the challenges and opportunities posed by the Covid-19 pandemic and the UN’s strategic roadmap for a TB-free world by 2030.

QIAGEN’s leading QuantiFERON-TB Gold Plus (QFT®-Plus) test plays an essential role in the global fight against TB, offering higher sensitivity and specificity for detection of TB infection than the century-old tuberculin skin test. QuantiFERON-TB Gold Plus only requires a single patient visit and is optimized to stimulate both CD8 and CD4 T cell responses. To date, more than 100 million QIAGEN QuantiFERON-TB tests have been distributed in over 130 countries, and they have been integrated into various national TB control strategies.

Reliably diagnosing and treating TB infections is crucial for TB control, as 25% of the world’s population is estimated to bear latent TB infection. This means that the affected patients show no symptoms of the disease. The infection can stay latent for years but may progress to active TB in some patients further transmitting and spreading the disease. According to the World Health Organization (WHO), more than 10 million people worldwide fall sick with TB yearly, and over one million lose their lives.  Especially by testing high-risk groups, QIAGEN’s QuantiFERON technology helps clinicians to make informed decisions about preventive treatment, which can finally end the vicious cycle of disease transmission.

To make the event accessible to as many people as possible, the Global TB Summit 2023 is free of charge and will be held virtually, closing with a hybrid day on October 19 that can be attended both virtually and onsite in London. Last year, more than 20 TB experts shared their knowledge with over 3,000 attendees from 120 countries. The entire program as well as the registration form can be found here: https://www.qiagen.com//applications/tb-management/events/tb-summit

About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2023, QIAGEN employed more than 6,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Media Contact:

Daniela Eltrop
Associate Director Public Relations
Germany: +49 2103 29 11676
Mobile: +49 152 01811676
daniela.eltrop@qiagen.com

Lisa Mannagottera
Associate Manager Public Relations
Germany: +49 2103 29 14181
Mobile: +49 152 01811381
lisa.mannagottera@qiagen.com

Dr. Thomas Theuringer
Senior Director Corporate Communications & Head Of External
Germany: +49 2103 29 11826
U.S.: +1 240 686 7425
The Netherlands: +31 773 55 66 66
thomas.theuringer@qiagen.com

IR Contacts

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
phoebe.loh@qiagen.com

Alexandra Koenig
Investor Relations Coordinator
+49 2103 29 11709
alexandra.koenig@qiagen.com

John Gilardi
Vice President
Head of Corporate Communications and Investor Relations
Germany +49 2103 29 11711
U.S. +1 240 686 2222
The Netherlands +31 773 55 66 66
john.gilardi@qiagen.com

SOURCE: QIAGEN